Physician profile
Nathan R Lighthizer
NPI 1366671497
$1,022,725.58
in general payments reported to CMS, 2019-2025
34 companies · $266K in 2025
The $266K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $65K · 2021: $68K · 2022: $98K · 2023: $109K · 2024: $315K · 2025: $266K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192K · Consulting Fee: $151K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $104K · Honoraria: $80K · Travel and Lodging: $28K · Acquisitions: $5,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192,202.41 |
| Consulting Fee | $150,557.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,824.26 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $104,200.00 |
| Honoraria | $80,125.00 |
| Travel and Lodging | $28,191.71 |
| Acquisitions | $5,685.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $158,752.69 | 2022-2025 | Optilight |
| Sun Pharmaceutical Industries INC. | $131,919.39 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Bausch & Lomb Americas INC. | $110,289.43 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Lkc Technologies, INC. | $93,802.85 | 2022-2025 | |
| Optovue, INC. | $81,326.55 | 2019-2021 | |
| Alcon Vision LLC | $54,476.39 | 2021-2025 | Tryptyr, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $53,589.65 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $53,046.55 | 2019-2025 | Tearcare System, Omni Surgical System |
| Reichert, INC. | $46,575.00 | 2020-2025 | Tono-Vera Tonometer US Starter Kit Human Rechargable |
| Dompe US, INC. | $42,831.44 | 2020-2025 | Oxervate |
| Lumibird Medical INC. | $40,720.89 | 2019-2025 | |
| Alcon Research LLC | $34,984.03 | 2022-2025 | Tryptyr |
| Novartis Pharmaceuticals Corporation | $33,642.01 | 2019-2023 | |
| Shire North American Group INC | $18,836.65 | 2019 | |
| Visionix USA, INC | $18,000.00 | 2024 | Optical Coherence Tomography Hoct-1f |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $12,420.31 | 2022-2025 | Tyrvaya, Phentolamine Mesylate |
| Abbvie INC. | $11,485.61 | 2022-2025 | |
| Thea Pharma INC. | $6,922.31 | 2022-2025 | Iyuzeh |
| Allergan, INC. | $5,184.18 | 2019-2022 | |
| Lumenis, INC | $3,000.00 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $2,787.73 | 2021-2025 | Forum, Clarus, Cirrus Hd-Oct |
| Glaukos Corporation | $1,805.32 | 2020-2025 | Radius Xr, Kxl System (Not Refurbished), Idosetr |
| Maculogix, INC. | $1,500.00 | 2020 | |
| Horizon Therapeutics Plc | $1,173.79 | 2019-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $974.72 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $939.18 | 2024-2025 | Cirrus 6000 With Angioplex, Cirrus Hd-Oct, Callisto Eye |
| Ivantis, INC | $743.67 | 2021 | |
| Ocular Therapeutix, INC. | $532.76 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $214.20 | 2021 | |
| Harrow Eye, LLC | $131.85 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $50.97 | 2019-2021 | |
| Quidel Corporation | $46.72 | 2022 | |
| Genzyme Corporation | $18.74 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Lighthizer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.